Antibodies having binding specificity to CD44 v7/8, (a.k.a. CD44 variant 7/8) and antibody-drug conjugates (ADCs) or chimeric antigen receptors comprising such. Also provided herein are uses the anti-CD44 v7/8 antibodies, the ADCs, or immune cells expressing the chimeric antigen receptors for therapeutic and diagnostic purposes.

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

Methods of treating a cancer, comprising administering to a subject: (i) a virus comprising nucleic acid encoding an antigen-binding molecule comprising: (a) an antigen-binding moiety specific for an immune cell surface molecule, and (b) an antigen-binding moiety specific for a cancer cell antigen; and (ii) an oncolytic virus, and/or (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen are disclosed. Also disclosed are articles and compositions for use in such methods.

Methods and CD44-modulating peptide compositions for treating or ameliorating ascites, for treating or ameliorating a tumor or cancer, wherein the compositions feature binding moieties such as monoclonal antibodies or fragments thereof specific for CD44 that inhibit CD44 activity, or CD44-modulating peptides that bind to and modulate activity of CD44, optionally featuring a pharmaceutically acceptable carrier. The binding moieties herein may be used with a secondary therapy. In some embodiments, the monoclonal antibody or fragment thereof binds to at least a portion of the cryptic region of CD44.

The present invention discloses a method for treating a subject suffering from a Flavivirus infection. The method includes a step of administering to the subject a pharmaceutical composition including a pharmaceutically effective amount of an anti-CD44 antibody.

A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.

The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding the RNA, production host cell lines comprising the RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of the RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of the RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.

This disclosure provides treatment kit that are capable of modulating the immune response. The treatment kit may also be used enhance the immunogenicity of antigens released from cell debris. Also provided are methods of using the treatment kit.

Methods and compositions related to intracellular delivery of gene editing proteins are provided. The invention relates to compositions and methods for transporting gene editing polypeptides, such as Cas9 or Cas12, into a cell ex vivo or in vivo. The invention includes a targeted active gene editing (TAGE) agent that includes an extracellular cell membrane binding moiety, e.g., an antigen binding polypeptide, a cell penetrating peptide (CPP), a ligand, or combinations thereof, that specifically binds to an extracellular cell membrane-bound molecule (e.g., a cell surface molecule), and a site-directed modifying polypeptide that recognizes a nucleic acid sequence. The extracellular cell membrane binding moiety (e.g., antigen binding polypeptide, CPP, or ligand) and the site-directed modifying polypeptide are stably associated such that the site-directed modifying polypeptide can be internalized into a cell, such as one displaying an extracellular cell membrane-bound molecule recognized by the extracellular cell membrane binding moiety.

Disclosed are methods for treating cancer in a subject. The methods typically include administering to the subject a therapeutic agent that inhibits aggregation of tumor cells.